Taiho Pharmaceutical Co., Ltd.
Clinical trials sponsored by Taiho Pharmaceutical Co., Ltd., explained in plain language.
-
New combo targets Hard-to-Treat stomach tumors
Disease control OngoingThis early-phase trial tests a new drug, pimitespib (TAS-116), combined with the standard drug imatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib. The study aims to find the safest dose, check for side effects, and see…
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug TAS-205 aims to help kids with duchenne walk better
Disease control OngoingThis Phase 3 trial tests whether TAS-205, an oral drug, can improve movement and safety in people with Duchenne muscular dystrophy. It includes 104 participants, both those who can walk and those who cannot. The study compares TAS-205 to a placebo over 52 weeks.
Phase: PHASE3 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:28 UTC